Unlock instant, AI-driven research and patent intelligence for your innovation.

Therapeutic agent for interstitial pneumonia

A technology of interstitial and therapeutic agents, applied in the field of interstitial pneumonia therapeutic agents, can solve problems such as ideas that have not been concretely existed, and achieve the effects of excellent affinity, excellent stability, and short half-life

Inactive Publication Date: 2009-11-18
LTT BIO PHARMA
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] To date, the idea of ​​using PC-SOD itself to treat interstitial pneumonia (in particular, the treatment of idiopathic interstitial pneumonia) has not concretely existed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic agent for interstitial pneumonia
  • Therapeutic agent for interstitial pneumonia
  • Therapeutic agent for interstitial pneumonia

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0068] The preparation of the therapeutic agent for interstitial pneumonia provided by the present invention can be carried out by using PC-SOD and sucrose by a well-known conventional method in pharmacy. It should be noted that the PC-SOD used in the formulation composition of the present invention is preferably in the form of a solution, frozen or freeze-dried.

[0069]Therefore, the therapeutic agent for interstitial pneumonia provided by the present invention contains PC-SOD stabilized by sucrose, and the therapeutic agent can be administered intravenously, preferably in a form suitable for injection or intravenous infusion. Forms suitable for injection or intravenous infusion are preferably infusion formulations, solutions, suspensions, emulsions, and time-dissolving solid formulations, and these formulations can be prepared according to the methods described in the Japanese Pharmacopoeia General Rules for Preparations.

[0070] The amount of the active ingredient PC-SOD ...

Embodiment

[0073] Hereinafter, the present invention will be described in more detail through a stability test and a test example (clinical test example) of administration to an actual patient with interstitial pneumonia.

[0074] It should be noted that, when administered, the safety of the PC-SOD of the present invention has been fully confirmed through animal experiments. The clinical trial examples described below are the trials conducted after obtaining the consent of the clinical trial subjects on the basis of fulfilling the obligation of informed consent to the patients and giving sufficient explanations.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A therapeutic agent for interstitial pneumonia is provided which effectively exploits the effect of superoxide dismutase (SOD). The therapeutic composition for interstitial pneumonia contains 10 to 100mg of lecithinized superoxide dismutase represented by the following general formula (I): SOD'(Q-B) m (I) (wherein SOD' is a residue of superoxide dismutase; Q is a chemical crosslink; B is a residue of lysolecithin having the hydrogen atom of the hydroxyl group at position 2 of its glycerol moiety removed; and m is the average number of lysolecithin molecules bound to one molecule of the superoxide dismutase and is an integer of 1 or greater) and further contains sucrose to give it a stable form suitable for intravenous administration.

Description

technical field [0001] The present invention relates to a therapeutic agent for interstitial pneumonia. Specifically, it relates to a therapeutic agent for interstitial pneumonia containing lecithinated superoxide dismutase (hereinafter, sometimes abbreviated as PC-SOD) as an active ingredient. Background technique [0002] Superoxide dismutase (hereinafter, sometimes abbreviated as SOD) was first extracted from the blood of cattle by Huber et al. in 1965 as an anti-inflammatory protein. It has been clarified that superoxide dismutase can specifically Scavenging superoxide anion (O 2 - ) of physiologically active proteins. In organisms, reactive oxygen species are mainly released by neutrophils, macrophages and other phagocytes for sterilization, but usually in relatively excess reactive oxygen species, there are various antioxidant substances represented by SOD, which defend against reactive oxygen species. Damage to normal cells. [0003] However, if active oxygen exis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/45A61K9/08A61K31/573A61K45/00A61K47/24A61K47/48A61P11/00A61P29/00A61K47/54
Inventor 白井厚治川岛辰男黑田敏久水岛裕村上雅弘福崎智美
Owner LTT BIO PHARMA